Opioid Adjuncts: Optimizing Opioid Therapy With Nonopioid Medications.

Clin Obstet Gynecol

Department of Obstetrics and Gynecology, University of North Carolina, Chapel Hill, North Carolina.

Published: March 2019

In this article, we describe a variety of medications that physicians managing outpatient chronic pain should familiarize themselves with to better aid their approach to multimodal pain therapy. Physicians should always consider the use of an adjuvant or coanalgesic drug as first-line treatments. Although many of these medications are not primarily analgesics, in clinical practice they have independent analgesic effects or synergistic analgesic properties when used with opioids. The use of adjunct analgesics reduces opioid-related adverse effects and optimizes pain management. Although there may be some medication overlap with this section and the ERAS section, the purpose of this article is to understand prolonged use in the outpatient setting to reduce opioid use or limit opioid dose with adjuvant therapy.

Download full-text PDF

Source
http://dx.doi.org/10.1097/GRF.0000000000000423DOI Listing

Publication Analysis

Top Keywords

opioid
4
opioid adjuncts
4
adjuncts optimizing
4
optimizing opioid
4
opioid therapy
4
therapy nonopioid
4
nonopioid medications
4
medications article
4
article describe
4
describe variety
4

Similar Publications

Background: In 2020, Maryland had the fourth-highest opioid overdose mortality rate in the USA. We describe substances identified in postmortem toxicology screening and designated as cause of death (COD) for overdose decedents in Maryland, including specific combinations of substances designated as COD.

Methods: We performed a retrospective analysis of N=5442 adult overdose decedents (ie, manner of death unintentional or undetermined) in Maryland between January 2020 and December 2021.

View Article and Find Full Text PDF

The first five years of implementing Missouri's medication first approach to opioid use disorder treatment: Plateaus, regressions, and underbellies of progress.

J Subst Use Addict Treat

January 2025

University of Missouri-St. Louis, Addiction Science, Missouri Institute of Mental Health, 1 University Blvd., Benton Hall, Room 206, St. Louis, MO 63121, USA.

Introduction: Missouri's Medication First ("MedFirst") approach promotes same-day and long-term low-threshold access to medications for opioid use disorder (MOUD). Since 2017, Missouri's SAMHSA-funded State Targeted and State Opioid Response (STR/SOR) grants have supported MedFirst services (both medical and psychosocial) for uninsured individuals with opioid use disorder at state-contracted treatment programs. Though MedFirst demonstrated early success, results - with attention to possible racial disparities - must be revisited after five years of implementation.

View Article and Find Full Text PDF
Article Synopsis
  • Substance use disorders among pregnant and postpartum individuals are increasing, highlighting the need for better education and intervention for healthcare providers.
  • The review covers the impact of various substances like nicotine, cannabis, and opioids on maternal and fetal health, along with treatment options.
  • It also discusses ethical and legal issues related to substance use during pregnancy, advocating for equitable, non-stigmatizing care practices.
View Article and Find Full Text PDF

Background & Aims: Buprenorphine and methadone are drugs used as medication for addiction treatment for patients with opioid use disorders (OUDs). However, scarce evidence indicates that they induce oxidative stress, which contributes to the deterioration of psychosocial parameters, thus complicating successful rehab. Therefore, a dietary antioxidant intervention such as pomegranate could be beneficial for that group of patients.

View Article and Find Full Text PDF

Focused Ultrasound Neuromodulation: Exploring a Novel Treatment for Severe Opioid Use Disorder.

Biol Psychiatry

January 2025

Department of Neuroscience, Rockefeller Neuroscience Institute, West Virginia University, Morgantown, WV, USA; Department of Behavioral Medicine and Psychiatry, Rockefeller Neuroscience Institute, West Virginia University, Morgantown, WV, USA. Electronic address:

Background: Opioid use disorder remains a critical healthcare challenge as current therapeutic strategies have limitations resulting in high recurrence and deaths. We evaluated safety and feasibility of focused ultrasound (FUS) neuromodulation to reduce substance cravings and use in severe opioid- and co-occurring substance use disorders.

Methods: This prospective, open-label, single-arm study enrolled 8 participants with severe, primary opioid use disorder with co-occurring substance use.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!